This webinar, led by Dr Kelly Olson, will discuss trends with fentanyl-associated polysubstance use and the complexities of clinical management in these populations.

Fentanyl detection rates have recently decreased, but fentanyl-associated polysubstance use remains significant and growing.  Overdose mortality data increasingly point to the co-involvement of stimulants in fentanyl-related deaths, which has been referred to as the "fourth wave" of the overdose epidemic.

Considering the current and emerging opioid and stimulant use patterns, Dr Olson will discuss trends in fentanyl positivity rates while focusing on the co-detection of methamphetamine, cocaine, and prescription opioids in the population using fentanyl.

She will also touch on the recent rising tide of heroin use, particularly in those using fentanyl, and consider positivity rate changes.

Finally, clinical challenges in the management (including medication-assisted therapies) of the co-use of opioids and stimulants will be discussed at length, including brain involvement in illicit drug psychosis.